Impax/GSK's Extended-Release Parkinson's Treatment IPX066 Aces Third Phase III Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Impax plans Q4 FDA submission, while GSK will approach European regulators in 2012.